Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes
Open Access
- 19 September 2011
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 2 (5), 213-225
- https://doi.org/10.1177/2042098611415566
Abstract
In the past, patients with hemophilia and inhibitors have had less-than-optimal treatment and have experienced more orthopedic complications than patients without inhibitors. Bypassing agents offer the potential to close treatment gaps between inhibitor and noninhibitor patients by helping the former better attain key treatment goals, including: facilitating early initiation of treatment and hemostatic control in hemarthroses; providing effective treatment in serious hemorrhagic episodes; and performance of major surgery. Effective treatment with a bypassing agent minimizes joint and/or muscle damage and potentially can serve as an effective prophylactic agent to minimize the number of hemarthroses experienced per year, thereby mitigating the development of arthropathy. The reported efficacy of the currently available bypassing agents ranges from approximately 50–80% (50–64% in controlled studies) for plasma-derived activated prothrombin complex concentrate (pd-aPCC) and 81–91% (in controlled studies) for recombinant activated factor VII (rFVIIa), including use in major orthopedic surgery. Both bypassing agents have undergone key improvements in their formulation and/or properties in recent years. The nanofiltered, vapor-heated formulation of pd-aPCC has diminished the risk of acquiring blood-borne viral infections and the room temperature stable formulation of rFVIIa allows more convenient storage, increased ease to dissolve and inject, and smaller volumes, thereby increasing overall ease of administration. Use of recommended dosing has been demonstrated to provide effective hemostasis with a minimal number of injections for both agents. In this paper, we review the individual characteristics of pd-aPCC and rFVIIa and discuss clinical data from studies conducted in inhibitor patients that demonstrate the potential benefits of these bypassing agents in this difficult-to-treat population, and underscore the potential opportunities to close the gap in care between inhibitor and noninhibitor hemophilic patients.Keywords
This publication has 85 references indexed in Scilit:
- Surgery in patients with haemophilia and high responding inhibitors: Izmir experienceHaemophilia, 2010
- Evidence supporting the use of recombinant activated factor VII in congenital bleeding disordersDrug Design, Development and Therapy, 2010
- Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech RepublicHaemophilia, 2009
- Overview of the human pharmacokinetics of recombinant activated factor VIIBritish Journal of Clinical Pharmacology, 2007
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Recombinant Factor VIIa (Eptacog Alfa)PharmacoEconomics, 2007
- Induced Tolerance in Hemophilia Patients with Antibodies against IX:CActa Medica Scandinavica, 1983
- The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIIINew England Journal of Medicine, 1981
- Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIIINew England Journal of Medicine, 1980
- A CLINICAL AND MEDICO‐SOCIAL STUDY OF HAEMOPHILIA IN SWEDENActa Medica Scandinavica, 1962